Invesco’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-167,178
| Closed | -$1.87M | – | 3718 |
|
|
2017
Q3 | $1.87M | Sell |
167,178
-166
| -0.1% | -$1.83K | ﹤0.01% | 2628 |
|
|
2017
Q2 | $1.84M | Buy |
167,344
+13,914
| +9% | +$139K | ﹤0.01% | 2623 |
|
|
2017
Q1 | $1.5M | Buy |
153,430
+20,143
| +15% | +$201K | ﹤0.01% | 2791 |
|
|
2016
Q4 | $1.44M | Sell |
133,287
-300,502
| -69% | -$3M | ﹤0.01% | 2810 |
|
|
2016
Q3 | $4.45M | Sell |
433,789
-539,051
| -55% | -$5.87M | ﹤0.01% | 2059 |
|
|
2016
Q2 | $12.7M | Buy |
972,840
+612,899
| +170% | +$8.03M | ﹤0.01% | 1328 |
|
|
2016
Q1 | $3.96M | Buy |
359,941
+94,320
| +36% | +$839K | ﹤0.01% | 2045 |
|
|
2015
Q4 | $2.44M | Buy |
265,621
+2,311
| +0.9% | +$19.3K | ﹤0.01% | 2391 |
|
|
2015
Q3 | $1.83M | Buy |
263,310
+17,836
| +7% | +$153K | ﹤0.01% | 2567 |
|
|
2015
Q2 | $2.41M | Buy |
245,474
+12,961
| +6% | +$118K | ﹤0.01% | 2496 |
|
|
2015
Q1 | $2.06M | Buy |
232,513
+94,112
| +68% | +$750K | ﹤0.01% | 2576 |
|
|
2014
Q4 | $1.21M | Buy |
138,401
+87,278
| +171% | +$706K | ﹤0.01% | 2835 |
|
|
2014
Q3 | $352K | Buy |
51,123
+15,364
| +43% | +$92.1K | ﹤0.01% | 3454 |
|
|
2014
Q2 | $188K | Hold |
35,759
| – | – | ﹤0.01% | 3732 |
|
|
2014
Q1 | $163K | Sell |
35,759
-43,674
| -55% | -$211K | ﹤0.01% | 3835 |
|
|
2013
Q4 | $400K | Buy |
79,433
+22,499
| +40% | +$108K | ﹤0.01% | 3554 |
|
|
2013
Q3 | $289K | Buy |
56,934
+27,831
| +96% | +$155K | ﹤0.01% | 3622 |
|
|
2013
Q2 | $144K | Buy |
+29,103
| New | +$138K | ﹤0.01% | 3799 |
|
Invesco's SCLN Position: Q4 2017 in Review
Invesco sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 167,178 shares — an estimated $1.87M sold.
Invesco first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $12.7M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Invesco reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Invesco sold 167,178 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.87M.
- Invesco first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Invesco's Sciclone Pharmaceuticals Inc position peaked at $12.7M in Q2 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Invesco's 13F filing for Q4 2017, filed 14 Feb 2018.